STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Active, not recruiting
- Small Cell Lung Cancer
- ETOPOSIDE - Usual
- ETOPOSIDE - Study
- North Bethesda, MarylandMedicine Invention Design, Inc. (MIDI) - IORG0007849
2021-08-30
Aug 30, 2021B
Active, not recruiting
- COVID-19
- Etoposide
- Boston, MassachusettsBoston Medical Center
2022-01-07
Jan 7, 2022A
Recruiting
- Glioblastoma Multiforme
- Tamoxifen
- Etoposide
- Edmonton, Alberta, CanadaCross Cancer Institute
2022-03-28
Mar 28, 2022P
Completed
- Effect of Drug
- +2 more
- Apatinib Mesylate
- ifosfamide and etoposide
- Beijing, Beijing, ChinaPeking University People's Hospital
2022-03-12
Mar 12, 2022B
Recruiting
- Recurrent Medulloblastoma
- Apatinib Combined With Temozolomide and Etoposide Capsules
- Beijing, ChinaBeijing Sanbo Brain Hospital
2022-02-10
Feb 10, 2022M
Active, not recruiting
- Leukemia
- Alemtuzumab
- +5 more
- Houston, TexasUniversity of Texas MD Anderson Cancer Center
2022-02-02
Feb 2, 2022N
Recruiting
- Germ Cell Tumor
- +2 more
- Etoposide
- Indianapolis, IndianaIndiana University Melvin & Bren Simon Cancer Center
2022-02-23
Feb 23, 2022U
Completed
- Leukemia
- +2 more
- Ciprofloxacin
- Etoposide
- Gainesville, FloridaUF Health Shands Cancer Hospital
2022-01-20
Jan 20, 2022L
Recruiting
- Extensive-stage Small-cell Lung Cancer
- ZKAB001
- +3 more
- Shanghai, Shanghai, ChinaShanghai Chest Hospital
2021-09-08
Sep 8, 2021C
Recruiting
- Triple Negative Breast Cancer
- oral etoposide + anlotinib
- Beijing, ChinaCancer Institute & Hospital. Chinese Academy of Medical Sciences
2021-07-15
Jul 15, 2021B
Active, not recruiting
- Small Cell Lung Cancer
- BMS-986012
- +4 more
- Barcelona, Spain
- +3 more
2021-11-08
Nov 8, 2021K
Recruiting
- Acute Myeloid Leukemia
- mitoxantrone + etoposide + gemtuzumab ozogamicin
- Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
2022-02-09
Feb 9, 2022P
Recruiting
- Ovarian Cancer
- Beijing, China
- +1 more
2021-08-27
Aug 27, 2021S
Not yet recruiting
- Small Cell Neuroendocrine Carcinoma of Bladder
- +2 more
- Atezolizumab
- +4 more
- Washington, District of Columbia
- +1 more
2022-03-28
Mar 28, 2022N
Not yet recruiting
- Extensive Stage Small Cell Lung Cancer
- [177Lu]Lu-DOTA-TATE
- +4 more
- (no location specified)
2022-04-05
Apr 5, 2022T
Recruiting
- Brain Tumor Recurrent
- Methotrexate
- +2 more
- Houston, TexasUTHealth & Children's Memorial Hermann Hospital
2021-10-27
Oct 27, 2021S
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
- Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
2021-06-03
Jun 3, 2021P
Recruiting
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Chidamide
- Etoposide + Cisplatin/Carboplatin
- Beijing, Beijing, China
- +2 more
2021-11-02
Nov 2, 2021S
Recruiting
- Treatment Refusal
- Gemcitabine
- +3 more
- Guangzhou, Please Select, ChinaSun Yat-sen University Cancer Center
2020-12-16
Dec 16, 2020Q
Not yet recruiting
- Extensive-stage Small-cell Lung Cancer
- QL1706
- +2 more
- Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
2022-03-25
Mar 25, 2022S
Active, not recruiting
- Testicular Neoplasms
- Seminoma
- Bleomycin Etoposide and Cisplatin
- Carboplatin
- Trondheim, NorwayInstitutt for kreftforskning og molekylær medisin, St Olavs Hosp
2021-11-05
Nov 5, 2021J
Recruiting
- Extensive-stage Small-cell Lung Cancer
- Changchun, ChinaJilin Cancer Hopspital
2021-09-05
Sep 5, 2021O
Completed
- Anaplastic Oligoastrocytoma
- +3 more
- Carboplatin
- +7 more
- Minneapolis, Minnesota
- +1 more
2022-03-11
Mar 11, 2022E
Recruiting
- Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Everolimus
- +3 more
- Atlanta, Georgia
- +3 more
2021-07-15
Jul 15, 2021S
Recruiting
- Acute Lymphoblastic Leukemia
- Seoul, Daehangno, Jongno-gu, Korea, Republic ofSeoul National University Hospital
2021-06-15
Jun 15, 2021